

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

KEY OPERATING DATA OF JIANGZHONG PHARMACEUTICAL FOR THE YEAR 2023

On 29 January 2024, Jiangzhong Pharmaceutical released its key operating data for the year 2023.

Jiangzhong Pharmaceutical Co., Ltd. (江中藥業股份有限公司) (“**Jiangzhong Pharmaceutical**”) is a company incorporated in the People’s Republic of China. The shares of Jiangzhong Pharmaceutical are listed on the Shanghai Stock Exchange. As of the date of this announcement, Jiangzhong Pharmaceutical is owned as to approximately 43.07% equity interest by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) through its non-wholly owned subsidiary, China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (華潤江中製藥集團有限責任公司). The Group controls an effective interest of approximately 22.11% of Jiangzhong Pharmaceutical, which is accounted for as a subsidiary of the Company.

According to the preliminary assessment by Jiangzhong Pharmaceutical, the total operating revenue of Jiangzhong Pharmaceutical for the year 2023 increased by approximately 13% compared to the previous year. The net profit attributable to the shareholders of Jiangzhong Pharmaceutical increased by approximately 18% compared to the previous year (the “**Jiangzhong Operating Results Estimate**”).

The Jiangzhong Operating Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. The annual report for the year ended 31 December 2023 to be disclosed by Jiangzhong Pharmaceutical shall prevail.

The financial information in this announcement is limited to Jiangzhong Pharmaceutical only and does not represent or provide a complete view of the operational of financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Beijing, 29 January 2024

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.